GEN Exclusives

More »

GEN News Highlights

More »
May 13, 2013

Mirna Initiates PI Trial for miRNA Candidate Cancer Drug

  • Mirna Therapeutics today said it has initiated a Phase I clinical trial for its microRNA-based cancer candidate MRX34, making it the first miRNA to advance into such study for cancer. MRX34 is an miRNA mimic of tumor suppressor miR-34, and delivered using a liposomal delivery formulation in-licensed from Marina Biotech.

    In a statement, Mirna CEO Paul Lammers called the trial “a landmark even for cancer drug development,” adding that “the preclinical profile of MRX34 across a range of tumors strongly suggests that miRNA-based therapeutics may represent a potent, new class of anticancer drugs working through a mechanism that affects multiple oncogenic pathways simultaneously.”

    The trial, which is expected to enroll up to 48 patients with unresectable primary liver cancer or metastatic cancer with liver involvement, will follow a standard oncology study design, involving an initial dose-escalation phase followed by an enrichment phase, the firm said.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »